Showing 741 - 760 results of 1,420 for search '"arthritis"', query time: 0.07s Refine Results
  1. 741
  2. 742
  3. 743
  4. 744
  5. 745
  6. 746
  7. 747

    Can the adherence to quality of care indicators for early rheumatoid arthritis in clinical practice reduce risk of hospitalisation?... by Carlo Alberto Scirè, Antonella Zambon, Greta Carrara, Anna Zanetti, Lisa Argnani

    Published 2020-09-01
    “…Objective To describe the adherence to quality of care indicators in early rheumatoid arthritis (RA) and to evaluate its impact on the risk of hospitalisation in a real-world setting.Design Retrospective cohort study.Setting Patients with early-onset RA identified from healthcare regional administrative databases by means of a validated algorithm between 2006 and 2012 in the Lombardy region (Italy).Participants The study cohort included 14 203 early-onset RA (71% female, mean age 60 years).Outcome measures For each patient, a summary adherence score was calculated starting from the compliance to six quality indicators: (1–2) methotrexate or sulfasalazine or leflunomide with/without glucocorticoids, (3–4) other disease-modifying antirheumatic drugs (DMARDs) with/without glucocorticoids, (5) early interruption of glucocorticoids, (6) early clinical assessment.The relationship between low, intermediate and high categories of the summary score and the 12-month risk of hospitalisation for all causes and for RA was assessed.Results During a follow-up of 1 year, 2609 hospitalisations occurred, of which 704 were for RA (main or secondary diagnosis) and 252 primarily for RA. …”
    Get full text
    Article
  8. 748

    The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1) by Peter H. Schafer, Peng Chen, Lorraine Fang, Andrew Wang, Rajesh Chopra

    Published 2015-01-01
    “…Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated effectiveness (versus placebo) for treatment of active psoriatic arthritis in the psoriatic arthritis long-term assessment of clinical efficacy (PALACE) phase III clinical trial program. …”
    Get full text
    Article
  9. 749
  10. 750
  11. 751
  12. 752
  13. 753
  14. 754
  15. 755
  16. 756

    Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23 by K. M. Darch, T. L. Holland, L. J. Spelman

    Published 2020-01-01
    “…Chronic plaque psoriasis and psoriatic arthritis are common autoimmune inflammatory conditions, often existing as comorbidities that have a significant impact on a patient’s quality of life. …”
    Get full text
    Article
  17. 757
  18. 758

    Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report by Yuya Fujita, Masao Nawata, Atsushi Nagayasu, Kazuki Someya, Kazuyoshi Saito, Yoshiya Tanaka

    Published 2019-01-01
    “…Baricitinib is a Janus kinase 1/2 (JAK1/2) inhibitor used in the treatment of rheumatoid arthritis. A 71-year-old woman with rheumatoid arthritis complicated by systemic sclerosis and type 1 diabetes that were resistant to multiple disease-modifying antirheumatic drugs started treatment with baricitinib. …”
    Get full text
    Article
  19. 759
  20. 760